IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1579-628

1 8.16.03

HALE et al

Group Art Unit:

AUG 1 5 2002

Serial No. 09/998,923

998.923 Examiner:

Filed:

December 3, 2001

Date: August 14, 2002

Title:

ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER

Assistant Commissioner for Patents

Washington, DC 20231

AUG 1 4 2002

TECH CENTER 1600/2900

Sir:

INFORMATION DISCLOSURE STATEMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment e minus highest number previously paid for e (at least 20) = 0 x \$ 18.00	\$	0.00				
Independent claims after amendment 0 minus highest number previously paid for 3 (at least 3) = 0 x \$ 84.00	\$	0.00				
If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)						
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)						
Terminal disclaimer enclosed, add \$ 110.00	\$	0.00				
First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00) Please enter the previously unentered , , filed Submission attached						
Subtotal	\$	0.00				
If "small entity," then enter half (1/2) of subtotal and subtract Applicant claims "small entity" status. Statement filed herewith	-\$	0.00				
Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$	0.00				
Assignment Recording Fee (\$40.00)	\$	0.00				
Other:		0.00				
TOTAL FEE ENCLOSED	\$	0.00				

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A <u>duplicate</u> copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

MJW:tat

NIXON & VANDERHYE P.C.

By Atty: Mary J. Wilson, Reg. No. 32,955

Signature:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

HALE et al Atty. Ref.: 1579-628

Serial No.: 09/998,923 Group Art Unit:

Filed: December 3, 2001 Examiner:

For: ZINC ALPHA-2-GLYCOPROTEIN AS INDICATOR OF CANCER



August 14, 2002

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents and Trademarks Washington, DC 20231 RECEIVED

AUG 1 5 2002

Sir:

TECH CENTER 1600/2900

Each enclosed document listed on the herewith Form PTO-1449 was cited in the attached International Search Report, dated August 2, 2002, issued in a counterpart International application not more than three months ago.

This IDS is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to comply fully.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith Form PTO-1449 with the

HALE et al -- Serial No.: 09/998,923

Examiner's initials in the left column per MPEP 609 are earnestly solicited.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

Mary J. Wilson Reg. No. 32,955

MJW:tat

1100 North Glebe Road

8th Floor

Arlington, Virginia 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100

NFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO. SE		SERIAL NO.	RIAL NO.			
		1579-628		09/998,923	9/998,923			
		APPLICANT			•			
		HALE et al						
(Use	several sheets if necessary)	FILING DATE		GROUP				
		December 3,	2001					
		U.S. PATI	ENT DOCUMENTS					
*EXAMINER				01.400	011001 400	FILING		
INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS_	SUBCLASS	IF APPRO	JPRIATE	
			,					
PE VO								
) · · · · · · · · · · · · · · · · · · ·			<u></u>					
1000			···		REC	-11 /5		
MIR	. Š				ILC	FIVE	<u>:U</u>	
	§				AUG	5 200	17	
WY TRACE	 				-	200	14	
				TI	CH CENT	R 1600	/2900	
	<u> </u>						<i></i>	
						<u></u>		
		FOREIGN PA	ATENT DOCUMENTS			TRANS	LATION	
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
							<u> </u>	
	OTHER DOCL	IMENTS (including	Author, Title, Date, Per	tinent pages.	etc.)	1		
	Todorov et al, "Purificat	ion and Characteriza	ation of a Tumor Lipid-mo	obilizing Factor	", Cancer R	esearch		
	58:2353-2358 (1998)		1.5		handial Manula	A		
	Bundred et al, "Zinc Alp Activity", Eur. J. Cancel		evels in Serum and Brea	ist Fluids: a Pot	entiai Mark	er of Apo	ocrine	
	Hale et al. "Zinc α-2-Gly	vcoprotein Is Expres	sed by Malignant Prostat	ic Epithelium a	nd May Ser	ve as a		
	Potential Serum Market	r for Prostate Cance	r", Clinical Cancer Resea	rch 7:846-853	(2001)			
	Lopez-Otin and Diamar	ndis, "Breast and Pro	ostate Cancer: An Analys lews 19(4):365-396 (1998	is of Common	Epidemiolo	gical, Ge	enetic,	
	and biochemical realu	ies , Endocrine Nevi	GW3 13(4).003-030 (1330	·/				
*Examiner			Date Considered					
Function Initial	functional sensitional substitution or a	not elitation in in conformance	with MPEP 609: Draw line through		rmance and not	considered	Include	

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)